XML 61 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Employee Benefit Plans (Tables)
 12 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
Schedule of Nonvested Share Activity
The following table summarizes the Company’s RSU, RSA, and PSA activity and related information as of and for the year ended December 31, 2019 (in millions, except per share amounts and years):
 
Outstanding RSUs, RSAs, and PSAs (4)
 
Number of Shares
 
Weighted Average
Grant-Date Fair
Value per Share
 
Weighted Average
Remaining
Contractual Term
(In Years)
 
Aggregate
Intrinsic
Value
Balance at December 31, 2018
17.4

 
$
25.32

 

 

RSUs granted(1)
7.6

 
25.06

 
 
 
 
RSUs assumed upon the acquisition of Mist(1)
0.1

 
25.81

 
 
 
 
RSAs assumed upon the acquisition of Mist(1)
0.7

 
27.20

 
 
 
 
PSAs granted (2)
2.1

 
25.30

 
 
 
 
RSUs vested(3)
(5.5
)
 
25.99

 
 
 
 
RSAs vested(3)
(0.2
)
 
25.32

 
 
 
 
PSAs vested(3)
(0.9
)
 
25.13

 
 
 
 
RSUs canceled
(2.3
)
 
25.97

 
 
 
 
RSAs canceled
(0.1
)
 
27.65

 
 
 
 
PSAs canceled
(1.4
)
 
21.53

 
 
 
 
Balance at December 31, 2019
17.5

 
$
25.30

 
1.1
 
$
430.9

 
 
 
 
 
 
 
 
As of December 31, 2019
 
 
 
 
 
 
 
Vested and expected-to-vest RSUs, RSAs, and PSAs
16.2

 
$
25.32

 
1.1
 
$
399.2

________________________________
(1) 
The weighted-average grant-date fair value of RSUs, RSAs, and PSAs granted and assumed or substituted during 2019, 2018, and 2017 was $25.26, $25.33, and $27.53, respectively. The grant date fair value of RSUs and PSAs was reduced by the present value of dividends expected to be paid on the underlying shares of common stock during the requisite and derived service period as these awards are not entitled to receive dividends until vested. During 2019, the Company declared a quarterly cash dividend of $0.19 per share of common stock on January 29, 2019, April 25, 2019, July 25, 2019 and October 24, 2019.
(2) 
Includes performance-based and market-based RSUs granted under the 2015 Plan according to their terms. The number of shares subject to PSAs granted represents the aggregate maximum number of shares that may be issued pursuant to the award over its full term. The aggregate number of shares subject to performance-based conditions that would be issued if performance goals determined by the Compensation Committee are achieved at target is 0.7 million shares. Depending on achievement of such performance goals, the range of shares that could be issued under these awards is zero to 1.0 million shares. The aggregate number of shares subject to market-based conditions that would be issued if market criteria are achieved at target is 0.2 million shares. Depending on achievement of such market criteria, the range of shares that could be issued under these awards is zero to 0.4 million shares.
(3) 
Total fair value of RSUs, RSAs, and PSAs vested during 2019, 2018, and 2017 was $170.0 million, $200.5 million, and $187.3 million, respectively.
(4) 
0.9 million shares of PSAs were modified in 2019, which relate to PSAs granted in 2018 and PSAs assumed by the Company in connection with acquisitions consummated in 2016. Compensation cost resulting from the modifications totaled $21.2 million to be recognized over the remaining terms of the modified awards.
Shares Available for Grant

The following table presents the stock activity and the total number of shares available for grant under the 2015 Plan (in millions):
 
Number of Shares
Balance as of December 31, 2018
21.9

Additional shares authorized
3.7

RSUs and PSAs granted(1)
(15.5
)
RSUs and PSAs canceled(1)(2)
6.5

Balance as of December 31, 2019
16.6

________________________________
(1) 
In May 2019, the 2015 Plan was amended, and the amendment removed the fungible share adjustment used to determine shares available for issuance. Under the original terms of the 2015 Plan, RSUs and PSAs with a per share or unit purchase price lower than 100% of the fair market value of the Company's common stock on the day of the grant were counted against shares authorized under the plan as two and one-tenth shares of common stock for each share subject to such award. Pursuant to the amendment, beginning on May 14, 2019, each share award granted under the 2015 Plan reduces the share reserve by one share and all share awards granted on May 14, 2019 and thereafter that are later forfeited, canceled or terminated are returned to the share reserve in the same manner. The number of shares subject to PSAs granted represents the maximum number of shares that may be issued pursuant to the award over its full term.

(2)
Canceled or expired options and canceled RSUs and PSAs under the 2006 Plan are no longer available for future grant under such plan; however, the number of shares available for grant under the 2015 Plan are increased by the amount of such canceled or expired options, RSUs or PSAs, as applicable, up to a maximum of 29.0 million additional shares of common stock, pursuant to the terms of the 2015 Plan.
Schedule Of Share-based Payment Award, Stock Options and Employee Stock Purchase Plan, Valuation Assumptions

The weighted-average assumptions used and the resulting estimates of fair value for ESPP and market-based RSUs were as follows:
 
Years Ended December 31,
 
2019
 
2018
 
2017
ESPP:
 
 
 
 
 
Volatility
27%
 
29%
 
25%
Risk-free interest rate
2.1%
 
1.9%
 
0.9%
Expected life (years)
1.2
 
1.2
 
0.5
Dividend yield
2.9%
 
2.7%
 
1.5%
Weighted-average fair value per share
$6.65
 
$6.93
 
$6.04
 
 
 
 
 
 
Market-based RSUs:
 
 
 
 
 
Volatility
25%
 
28%
 
30%
Risk-free interest rate
2.4%
 
2.4%
 
1.9%
Dividend yield
2.8%
 
2.6%
 
1.4%
Weighted-average fair value per share
$27.32
 
$28.39
 
$19.30
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs
Share-based compensation expense associated with stock options, RSUs, RSAs, PSAs, and ESPP was recorded in the following cost and expense categories in the Company's Consolidated Statements of Operations (in millions):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Cost of revenues - Product
$
5.7

 
$
6.3

 
$
4.6

Cost of revenues - Service
17.3

 
18.0

 
17.5

Research and development
94.0

 
120.6

 
86.6

Sales and marketing
56.0

 
51.1

 
55.6

General and administrative
29.2

 
21.1

 
23.2

Total
$
202.2

 
$
217.1

 
$
187.5
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award
The following table summarizes share-based compensation expense by award type (in millions):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Stock options
$
7.7

 
$
0.4

 
$
0.5

RSUs, RSAs, and PSAs
176.5

 
198.2

 
171.3

ESPP
18.0

 
18.5

 
15.7

Total
$
202.2

 
$
217.1

 
$
187.5